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earch 68 (2010) 399–401Journal of Psychosomatic ResThe way forward: A case for longitudinal population-based studies in the
field of functional somatic syndromesThis special issue is focused on functional somatic
syndromes or disorders (FSDs): syndromes that do not
have a known underlying pathophysiology. Among the most
important examples are irritable bowel syndrome (IBS),
chronic fatigue syndrome (CFS), and fibromyalgia (FM).
Although there is an ongoing debate between the lumpers
(who argue that all FSDs are in fact manifestations of one
single disorder) and splitters (who argue that despite
communalities, the differences should not be ignored) [1],
most researchers currently agree that FSDs share at least a
common core. It is increasingly recognized that FSDs are not
discrete diseases but heterogeneous clusters of fluctuating
common functional symptoms with no clear boundaries
between healthy and disordered. Remarkably, we have not
yet translated this increasing knowledge into our research
designs. Despite the fact that we do not know how many
symptoms a person needs of which types for how long to
become a case of what exactly, the field of FSDs is filled with
cross-sectional case-control studies. In this editorial, I will
identify some of the problems associated with the current
approach, after which I will make a case for longitudinal
population-based studies as the way forward to further
increase our knowledge on the etiology of FSDs.
Generally speaking, well-performed case-control studies
may be as informative and valid as cohort studies [2].
However, when case-control designs are used to study the
etiology of FSDs, specific problems arise.
First, it is unclear whether the current diagnostic criteria that
are based on the presence of specific symptoms are valid. This
is illustrated by the two more or less competing approaches in
the literature. One set of studies is investigating symptom
patterns across FSDs [3], suggesting that symptoms are largely
shared between FSDs.At the same time, a second set of studies
is investigating symptom patterns within specific FSDs. These
studies increasingly recognize symptomatic subgroups within
specific syndromes. For example, IBS is often split into
constipation and diarrhea predominant [4], whereas factor
analyses have defined subtypes of FM [5] and CFS [6]. Thus,
on the one hand, several FSDs are regarded as manifestations
of a single underlying disorder, whereas on the other hand,
specific FSDs are split in subsyndromes. Both approaches
question the validity of the current diagnostic boundaries.0022-3999/09/$ – see front matter © 2010 Elsevier Inc. All rights reserved.Second, case-control studies typically compare patients
with a diagnostic label for their symptoms with patients
without these symptoms for the presence of presumed risk
factors. In case of FSDs, both the presumed risk factors and
the prognosis might be influenced by the presence of a
diagnostic label. In order to understand this, it is important to
realize that the core symptoms of FSDs are very common in
the general population. For example, many people in the
general population fulfill the criteria for CFS, although only
a minority of them receives a formal diagnosis. There are no
objective parameters that are able to distinguish states of
FSDs and health; instead, the diagnoses are purely based on
the reported symptoms and the exclusion of other explana-
tions for them. It is conceivable that receiving a syndrome
label is not only related to symptom severity but also to
personal characteristics including help-seeking behavior,
beliefs and expectations [7]. This implies that personality
characteristics that are different between FSDs cases and
controls might be more related to the labeling of functional
symptoms than to the development of them. This problem is
further amplified by the potential of an FSDs label to worsen
prognosis [8].
Third, the diagnostic criteria of different FSDs include
different temporal criteria. According to the internationally
accepted criteria, a CFS diagnosis requires persistent or
relapsing fatigue of six or more consecutive months, a
diagnosis of FM widespread pain for at least three months,
and a diagnosis of IBS recurrent abdominal pain or discomfort
at least three days per month during the previous three
months. This implies that differences between risk factors for
FSDs that are found in case-control studiesmight be related to
the chronicity of symptoms rather than to their type. It is
important to note that case-control studies in the FSDs field
are typically based on prevalent and not incident cases.
Fourth, case-control studies have to define a threshold for
caseness, and this also has consequences for the control
group. Typically, the international criteria are used, and
controls are not allowed to have any symptoms. For
example, the case definition for IBS requires having
symptoms at least three days per month during the previous
three months. This means that people having symptoms for
one or two days per month, or only during the previous two
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symptoms that characterize IBS are common, these groups of
people with subthreshold symptoms might be quite substan-
tial. On the other hand, as controls, people without any IBS-
related symptoms are often included, and this is also a highly
specific group. The severity threshold leads to a loss of
information, while in fact this threshold is debatable.
Fifth, different FSDs have different research traditions. If
risk factors are differentially associated with FSDs, it is
sometimes not obvious whether these are real differences or
whether they are due to methodological differences in the
research field of FSDs. For example, studies toward stress-
axes responses in IBS often use colorectal distension as a
stressor, in contrast to studies in other syndromes that more
often use pharmacological or psychological challenges.
In summary, case-control studies are complicated in the
study of the etiology of functional syndromes. Since we
assume that FSDs are not discrete diseases, we need to
translate this view on FSDs into our research designs.
In order to choose the most informative research design to
study the etiology of FSDs, it is important to first take a
closer look at the etiology of FSDs. The fact that FSDs
appear to be composed of symptomatic subgroups implies
that different etiological trajectories might result in a specific
FSD. At the same time, it is evident that many risk factors are
shared between FSDs, suggesting that largely comparable
etiological trajectories might result in different FSDs. This
apparent paradox is elucidated by Rothman's [2] model of
causation. In this model, a disease is the end result of an
etiological trajectory that is composed of component causes,
which are the conditions and events contributing to the
etiology of a disease. An example of a candidate component
cause for FSDs is Campylobacter gastroenteritis, which is
prospectively linked to an increased risk of the development
of IBS [9,10]. However, the vast majority of patients with
this infection never develops IBS, indicating that this
infection is not a sufficient cause. In Rothman's model, the
onset of a disease is equivalent to the completion of a
sufficient cause. A sufficient cause is a set of component
causes that inevitably produce disease and can be interpreted
as an etiological trajectory to disease. Interestingly, different
sufficient causes could be the start of the same disease
(etiological heterogeneity within disorders). In biology, this
is known as the concept of equifinality: the same end state
may be achieved via many different trajectories. If a
component cause is absent in a given person, and the person
still gets the disease, it means that the component cause is not
a necessary cause and this person has developed the disease
via an alternative sufficient cause. For example, the majority
of IBS patients probably never had Campylobacter gastro-
enteritis. In addition, sufficient causes leading to different
FSDs might have highly overlapping component causes
(etiological homogeneity among disorders). For example,
Campylobacter gastroenteritis is also prospectively linked to
an increased risk of the development of CFS, although to a
lesser degree compared to IBS [10].Thus, there are several etiological trajectories to disease
in FSDs. Some of these trajectories might be largely shared
between FSDs, other trajectories might be specific for
FSD subtypes, and largely different trajectories might result
in the same FSD. One important consequence of the
heterogeneity in etiological trajectories is that, by treating
FSDs as homogeneous entities, the expected effect sizes of
risk factors are low and the power of studies consequently
limited. This is due to the fact that risk factors that are only
involved in a subsample of etiological trajectories are
diluted by the etiological trajectories (sufficient causes) that
do not contain that specific risk factor (component cause).
It is evident that large samples are needed to study
etiological heterogeneity.
In my opinion, the complex etiology of FSDs can only be
further elucidated by studies meeting the following
characteristics.
First, studies need to be longitudinal, for several reasons.
Longitudinal research is the only way to characterize the
etiological trajectories that are relevant among and across
disorders and thus the only research design that fully
acknowledges the complex etiology that is conceptually
recognized. Longitudinal studies will also identify which
correlates of FSDs are mere consequences or epiphenomena
of the FSD instead of contributing to the etiology. As an
example, a high incidence of specific viral antibodies in CFS
patients could indicate a role of these viruses in the etiology
or could reflect an altered immune function that may be
cause or consequence of the disease [11]. It is important to
realize that consequences of outcomes are likely more highly
correlated with the outcomes than are risk factors [12]. In
addition, longitudinal studies have the potential to improve
diagnostic criteria. Longitudinal studies toward symptom
patterns over time could contribute to an empirically based
typology of different FSDs and thus provide an alternative
perspective to that offered by the current diagnostic criteria.
A similar approach has already been useful in the study of
depression and anxiety [13]. Such study toward symptom
trajectories over time could approach the question whether
FSDs are characterized by FSD-specific symptom clusters or
whether they only differ in their current concerns or in the
relative severity of symptoms.
Second, we need population-based studies instead of
studies comparing clinical samples with healthy controls.
This will avoid the problem of studying labeling instead of
existence of symptoms, while at the same time guaranteeing
that all participants in the whole range of health to disease
add to the results. In addition, population-based studies
enable us to investigate several different FSD end points
without much additional work. As such, a population-based
cohort can give an integrated estimate of the FSD-related
health effects of a given component cause. The main
drawback of a large population cohort is the costs associated
with repeated measurements of several component causes
and clinical end points. One solution for this problem is to
identify ongoing cohort studies that already include relevant
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are relevant for the study of the etiology of FSDs. An
additional advantage is that these cohorts are usually focused
around the objective detection of medically explained
diseases and therefore enable to exclude objectively
determined pathologies.
Third, as clinical end points, we should study diversity,
severity and chronicity of functional symptoms in addition to
the existence of a specific FSD. Thus, we will avoid the
problems in case definition (questionable validity of
diagnostic boundaries, the arbitrariness of the threshold for
caseness and the different temporal criteria) while still being
able to translate new to existing literature. In addition, this
will enable to integrate findings in different syndromes. It
would be a major step forward if we identified a gold
standard for the measurement of functional symptoms.
Although using a specified instrument may not be possible
in all studies, it will be possible to validate existing
instruments against this gold standard.
It is time that specialists from different fields unite their
forces in order to come to a shared approach. This will finally
make clear if FSDs are separate entities in real life or just in
the minds of the observers.
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